Effects of Tamoxifen on Endometrial Carcinogenesis in Mice
Authors:
- 1 May 1998
- journal article
- research article
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 89 (5) , 502-509
Abstract
Two experiments were conducted to determine the effect of tamoxifen (TAM) in mouse endometrium in comparison with that of 17β‐estradiol (E2). In a medium‐term assay, TAM as well as E2 treatment semi‐dose‐dependently increased the levels of fos/jun mRNA and their oncoproteins (Fos/Jun). The long‐term effect of TAM on mouse endometrial carcinogenesis was also examined in the following model. A total of 150 female ICR mice, 12–13 weeks of age, were used. Of these, 125 mice received an injection of N‐methyl‐N‐nitrosourea (MNU) solution (1 mg/100 g body weight) into their left uterine tube and saline into the right. One week later, they were divided into four groups: groups 1 (35 mice) and 2 (30 mice) were given 25 ppm and 5 ppm E2‐containing diet, respectively, while group 3 (30 mice) was fed 5 ppm TAM‐containing diet. Group 5 (30 mice) was fed basal diet alone. The remaining 25 mice (group 4) received 5 ppm TAM‐containing diet alone. At the termination of the experiment (30 weeks), endometrial carcinomas were confirmed to be present in the groups exposed to MNU. TAM increased the incidence of preneoplastic lesions of the endometrium, while E2 enhanced the occurrence of the carcinoma. No carcinomas were found in the group given TAM alone. In the ovaries, corpora lutea were lacking in most of the mice exposed to TAM, suggesting that the animals were not cycling. Such findings indicate that TAM has an enhancing effect on endometrial carcinogenesis in mice, probably via a mechanism involving overexpression of Fos/Jun proteins.Keywords
This publication has 39 references indexed in Scilit:
- Overexpressions of c-fos/jun mRNA and their oncoproteins (Fos/Jun) in the mouse uterus treated with three natural estrogensCancer Letters, 1995
- Rare occurrence of p53 and ras gene mutations in preneoplastic and neoplastic mouse endometrial lesions induced by N-methyl-N-nitrosourea and 17β-estradiolCancer Letters, 1995
- Enhancing Effects of Estrogens on Endometrial Carcinogenesis Initiated by N‐Methyl‐N‐nitrosourea in ICR MiceJapanese Journal of Cancer Research, 1993
- The case for clinical trials of tamoxifen for prevention of breast cancerThe Lancet, 1992
- NIH Fends Off Critics of Tamoxifen StudyScience, 1992
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- Endometrial lesions in patients undergoing tamoxifen therapyInternational Journal of Gynecology & Obstetrics, 1991
- Induction of c-fos gene and protein by growth factors precedes activation of c-mycNature, 1984
- Platelet-derived growth factor induces rapid but transient expression of the c-fos gene and proteinNature, 1984
- 243. Antitumour activity of the antiestrogen ICI 46,474 (Tamoxifen) in the dimethylbenzanthracene (DMBA)—induced rat mammary carcinoma modelJournal of Steroid Biochemistry, 1974